[Treatment of parkinsonian syndromes by bromocriptin].
Nine patients suffering from Parkinson's disease and 2 cases of Parkinsonian syndrome were treated with bromocriptine, for 41 to 117 days, with a daily dose of 20 to 40 mg. The results were very good in 4 cases, satisfactory in 6 and nil in one case. Improvement concerned akinesias, rigidity and tremor, and was more marked in patients with more advanced signs. In 2 patients, amantadine was stopped. The dose of L-dopa was decreased by 2/3 without any change in clinical condition and L-dopa could be withdrawn in 5 cases out of 8. Bromocriptine appears to be an interesting development in the treatment of Parkinson's disease.
D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy; D009325:Nausea / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*
D004873:Ergolines; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine
Traitement des syndromes parkinsoniens par la bromocriptine